Head-To-Head Contrast: NewLink Genetics (NLNK) vs. OpGen (OPGN)

NewLink Genetics (NASDAQ: NLNK) and OpGen (NASDAQ:OPGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Risk & Volatility

NewLink Genetics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, OpGen has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.


This table compares NewLink Genetics and OpGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NewLink Genetics -229.19% -63.39% -47.83%
OpGen -533.47% -1,289.51% -234.78%

Earnings & Valuation

This table compares NewLink Genetics and OpGen’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NewLink Genetics $35.77 million 8.89 -$85.15 million ($2.44) -3.52
OpGen $4.03 million 2.43 -$19.16 million ($0.62) -0.28

OpGen has lower revenue, but higher earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than OpGen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

52.6% of NewLink Genetics shares are owned by institutional investors. Comparatively, 11.8% of OpGen shares are owned by institutional investors. 13.7% of NewLink Genetics shares are owned by company insiders. Comparatively, 31.8% of OpGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NewLink Genetics and OpGen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewLink Genetics 0 0 6 0 3.00
OpGen 0 0 2 0 3.00

NewLink Genetics presently has a consensus price target of $25.67, suggesting a potential upside of 199.15%. OpGen has a consensus price target of $1.00, suggesting a potential upside of 478.03%. Given OpGen’s higher probable upside, analysts clearly believe OpGen is more favorable than NewLink Genetics.


NewLink Genetics beats OpGen on 8 of the 12 factors compared between the two stocks.

NewLink Genetics Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

OpGen Company Profile

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply